An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
about
JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3Insulin-like growth factor-I augments erythropoietin-induced proliferation through enhanced tyrosine phosphorylation of STAT5Principles of interleukin (IL)-6-type cytokine signalling and its regulationInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathwayT cell receptor-induced calcineurin activation regulates T helper type 2 cell development by modifying the interleukin 4 receptor signaling complexJanus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation.Characterization of the cytoplasmic domain of interleukin-13 receptor-alphaConstitutive activation of STAT transcription factors in acute myelogenous leukemiaInterleukin-1beta activates a short STAT-3 isoform in clonal insulin-secreting cellsSTAT protein recruitment and activation in c-Kit deletion mutantsVoting-based cancer module identification by combining topological and data-driven propertiesA dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling.Signaling through Gp130: toward a general scenario of cytokine action.Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells.Jak2-Stat5 interactions analyzed in yeast.Jaks, STATs, Cytokines, and Sepsis.New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domainMSCA: a spectral comparison algorithm between time series to identify protein-protein interactions.JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.The molecular basis of IL-21-mediated proliferation.Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.Detection of a functional hybrid receptor gammac/GM-CSFRbeta in human hematopoietic CD34+ cells.Hematopoietic cell survival signals are elicited through non-tyrosine-containing sequences in the membrane-proximal region of the erythropoietin receptor (EPOR) by a Stat5-dependent pathway.Interleukin 21: a cytokine/cytokine receptor system that has come of ageContributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.The erythropoietin receptor: molecular structure and hematopoietic signaling pathways.Leukemia inhibitory factor: a paracrine mediator of bone metabolism.Activation and functional analysis of Janus kinase 2 in BA/F3 cells using the coumermycin/gyrase B system.Activation of target signal transducers utilizing chimeric receptors with signaling-molecule binding motifs.A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation.Jamip1 (marlin-1) defines a family of proteins interacting with janus kinases and microtubules.Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling.Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase.Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line.Activation of STAT5 by IL-4 relies on Janus kinase function but not on receptor tyrosine phosphorylation, and can contribute to both cell proliferation and gene regulation.Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery
P2860
Q24306803-398B1021-4F54-4DF7-8B7C-771E77419173Q24308850-517C18D3-D3FE-4E44-94D1-172392C68832Q24530173-B54F6D48-5E10-4060-843A-7A949ABB7575Q24531184-2A76916B-48F7-4F73-8DCC-30BC5D175837Q24645598-1AB809DD-A8B9-454E-A71E-2FF1DFEFBAACQ24806655-A855F1CB-60A5-40FC-8DDF-9111F73F8975Q28139906-44BF295D-C3D1-4636-A994-F43BD206CCCDQ28207618-CCC9D355-CD92-47BE-89DA-640EA15DC02FQ28295615-314E11DB-3545-4B98-8BD4-CB31DC675058Q28634147-34186182-497B-4FEA-9908-799EA586BF79Q30661179-0E485CC2-65E3-49CE-BB0A-138207BE55BEQ31794325-3DDB985C-E2F0-48BB-AC9B-59A342F3925EQ33792910-3507F385-5A89-4514-A495-F9B9FC2A958CQ33961743-FBA813D2-5B4D-4380-BE20-DE09379D217DQ34098712-DC15DAF5-8987-44EB-9C93-558AE3BC7A71Q34231824-0D1DABA8-35C4-4081-A0C4-4D12811D0800Q34467000-5233514B-39BD-4994-BE9D-691761F2B812Q34987949-0AB92299-CEC9-4B93-895A-6662F512910EQ34994147-3FB6DD8D-655E-4B7D-AB63-59C19EA69230Q35627296-79AAF7F6-05BF-4A17-B766-DE11A9117A0CQ35635353-9DC103FB-3241-4E08-B2E1-2041C949F938Q35828741-540A234D-BAC3-42C0-9D5B-F61DB279AF1DQ35849172-CA3B64DC-BA47-460E-BE41-209404F24015Q36370615-D7BE02DB-5E98-4917-81F8-394933C554E3Q36664588-844D9561-13F3-4A6B-A2B4-A2C4CC95E85AQ36803809-70D49012-8008-4440-A0EF-4C5F52CCB235Q37109227-6F5C92AE-6E51-45D8-B779-3AEB6AC4327AQ37278507-3C1FC681-47A8-4EF1-B027-BBBFF0204864Q37838684-4E12C874-85C3-4584-BF29-675B02A54E8DQ37981265-6A2E5DA9-AEB2-48CB-94FB-31B5A7A9A054Q38614149-C6124813-99C1-4A12-9DD9-A3A15CB8FD9DQ39415399-373ECC82-3611-4E20-9902-8D12AF2721EBQ39772287-DDEB2451-260C-46F9-BDDC-5A8F0BA9DAE5Q39989369-22531DA2-141B-4F50-A706-C507EFBD42C9Q40531183-2033DAC5-8476-4B2C-B3EA-9EAAFD95B1BBQ40563242-B405BFF8-82CC-4386-AA9B-2E9AD7C2C5DBQ40744434-D4D28838-EC32-451C-9A63-17FE3A7FA7F0Q40894492-D9E268BF-1A53-4E99-8A18-F9FEFC3D317DQ40939460-D4CFAE2E-4268-40E8-B6F2-4E04CE442DD5Q40971179-1372D3BA-A5AB-495F-B0C4-AEC4A8F2FA3A
P2860
An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
An alternative pathway for STA ...... eraction between JAK and STAT.
@ast
An alternative pathway for STA ...... eraction between JAK and STAT.
@en
An alternative pathway for STA ...... eraction between JAK and STAT.
@nl
type
label
An alternative pathway for STA ...... eraction between JAK and STAT.
@ast
An alternative pathway for STA ...... eraction between JAK and STAT.
@en
An alternative pathway for STA ...... eraction between JAK and STAT.
@nl
prefLabel
An alternative pathway for STA ...... eraction between JAK and STAT.
@ast
An alternative pathway for STA ...... eraction between JAK and STAT.
@en
An alternative pathway for STA ...... eraction between JAK and STAT.
@nl
P2093
P356
P1433
P1476
An alternative pathway for STA ...... eraction between JAK and STAT.
@en
P2093
K Nakajima
K Sugiyama
M Takahashi-Tezuka
T Yamaguchi
Y Fujitani
Y Yamanaka
P2888
P304
P356
10.1038/SJ.ONC.1200907
P407
P577
1997-02-01T00:00:00Z
P5875
P6179
1020767877